BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24332391)

  • 1. Differential effects of cell adhesion, modulus and VEGFR-2 inhibition on capillary network formation in synthetic hydrogel arrays.
    Nguyen EH; Zanotelli MR; Schwartz MP; Murphy WL
    Biomaterials; 2014 Feb; 35(7):2149-61. PubMed ID: 24332391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
    Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
    Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of late outgrowth endothelial progenitor cell and umbilical vein endothelial cell responses to thromboresistant collagen-mimetic hydrogels.
    Munoz-Pinto DJ; Erndt-Marino JD; Becerra-Bayona SM; Guiza-Arguello VR; Samavedi S; Malmut S; Reichert WM; Russell B; Höök M; Hahn MS
    J Biomed Mater Res A; 2017 Jun; 105(6):1712-1724. PubMed ID: 28218444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for 3D environments that support human mesenchymal stem cell viability using hydrogel arrays.
    Jongpaiboonkit L; King WJ; Murphy WL
    Tissue Eng Part A; 2009 Feb; 15(2):343-53. PubMed ID: 18759676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant RGD-disintegrin DisBa-01 blocks integrin α
    Danilucci TM; Santos PK; Pachane BC; Pisani GFD; Lino RLB; Casali BC; Altei WF; Selistre-de-Araujo HS
    Cell Commun Signal; 2019 Mar; 17(1):27. PubMed ID: 30894182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrogel arrays formed via differential wettability patterning enable combinatorial screening of stem cell behavior.
    Le NNT; Zorn S; Schmitt SK; Gopalan P; Murphy WL
    Acta Biomater; 2016 Apr; 34():93-103. PubMed ID: 26386315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interplay between human MSCs and HUVECs in 3D spheroids laden in collagen/fibrin hydrogels for bone tissue engineering.
    Heo DN; Hospodiuk M; Ozbolat IT
    Acta Biomater; 2019 Sep; 95():348-356. PubMed ID: 30831326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of osteoglycin promotes angiogenesis in limb ischaemia mouse models via modulation of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 signalling pathway.
    Wu QH; Ma Y; Ruan CC; Yang Y; Liu XH; Ge Q; Kong LR; Zhang JW; Yan C; Gao PJ
    Cardiovasc Res; 2017 Jan; 113(1):70-80. PubMed ID: 28069703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.
    Arao T; Matsumoto K; Furuta K; Kudo K; Kaneda H; Nagai T; Sakai K; Fujita Y; Tamura D; Aomatsu K; Koizumi F; Nishio K
    Anticancer Res; 2011 Sep; 31(9):2787-96. PubMed ID: 21868521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary study on the effect of vascular endothelial growth factor-loaded self-assembled peptide hydrogel on angiogenesis and vascularization of human umbilical vein endothelial cells].
    Zhang RJ; Wang XZ; Liu Y; Zheng SG
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2020 Oct; 55(10):757-764. PubMed ID: 33045788
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of FGF2 and PEG hydrogel matrix properties on hMSC viability and spreading.
    King WJ; Jongpaiboonkit L; Murphy WL
    J Biomed Mater Res A; 2010 Jun; 93(3):1110-23. PubMed ID: 19768790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features.
    Nieminen T; Toivanen PI; Rintanen N; Heikura T; Jauhiainen S; Airenne KJ; Alitalo K; Marjomäki V; Ylä-Herttuala S
    Biochim Biophys Acta; 2014 Jan; 1840(1):454-63. PubMed ID: 24112971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A peptide functionalized poly(ethylene glycol) (PEG) hydrogel for investigating the influence of biochemical and biophysical matrix properties on tumor cell migration.
    Singh SP; Schwartz MP; Lee JY; Fairbanks BD; Anseth KS
    Biomater Sci; 2014 Jul; 2(7):1024-1034. PubMed ID: 25105013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priming Endothelial Cells With a Melanoma-Derived Extracellular Matrix Triggers the Activation of αvβ3/VEGFR2 Axis.
    Helal-Neto E; Brandão-Costa RM; Saldanha-Gama R; Ribeiro-Pereira C; Midlej V; Benchimol M; Morandi V; Barja-Fidalgo C
    J Cell Physiol; 2016 Nov; 231(11):2464-73. PubMed ID: 27420801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway.
    Weng WT; Huang SC; Ma YL; Chan HH; Lin SW; Wu JC; Wu CY; Wen ZH; Wang EM; Wu CL; Tai MH
    Biochim Biophys Acta; 2014 Jun; 1840(6):1850-60. PubMed ID: 24530634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGFR2 signalling contributes to increased endothelial susceptibility to TNF-α under chronic non-uniform shear stress.
    Urschel K; Garlichs CD; Daniel WG; Cicha I
    Atherosclerosis; 2011 Dec; 219(2):499-509. PubMed ID: 22019447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.
    Dong F; Zhou X; Li C; Yan S; Deng X; Cao Z; Li L; Tang B; Allen TD; Liu J
    Cancer Biol Ther; 2014; 15(11):1479-88. PubMed ID: 25482945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.